Immunovant, Inc. (IMVT): Shareholders' Equity
$852.59M
As of 2026-03-31
$735.39M
As of 2026-06-30
+33.0%
3-year compound annual growth
+16.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $852.59M | +20.5% | 2026-05-20, Balance as of period end |
| 2025-03-31 | $707.45M | +14.5% | 2026-05-20, Balance as of period end |
| 2024-03-31 | $617.76M | +70.4% | 2026-05-20, Balance as of period end |
| 2023-03-31 | $362.49M | -22.8% | 2025-05-29, Balance as of period end |
| 2022-03-31 | $469.82M | +20.0% | 2023-05-22, Balance as of period end |
| 2021-03-31 | $391.48M | +316.2% | 2022-06-08, Balance as of period end |
| 2020-03-31 | $94.07M | n/m | 2021-06-01, Balance as of period end |
| 2019-03-31 | $7.34M | n/a | 2020-06-29, Balance as of period end |
| 2018-07-06 | -$411.0K | n/a | 2020-06-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 2026-03-31 | $852.59M | +20.5% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $765.28M | -33.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $698.58M | -1.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $381.03M | +5.6% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $508.59M | -29.0% |
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $1.01B | -17.6% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $752.60M | +2.6% |
| Novavax Inc (NVAX) | 2025-12-31 | -$127.75M | n/m |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.22B | +28.9% |
Compare IMVT, VIR, IOVA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗